Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* is a healthy South Korean male or female who is 42 to 90 days of age at the time of signing informed consent~* has a parent or legally acceptable representative who understands study procedures, alternative treatments available, and risks involved and voluntarily agrees to participate by signing informed consent~Exclusion Criteria:~* has a history of invasive pneumococcal disease or known history of other culture positive pneumococcal disease~* has known hypersensitivity to pneumococcal conjugate vaccine, any licensed pediatric vaccine to be administered concomitantly, or any diphtheria toxoid-containing vaccine~* has had a recent febrile illness (rectal temperature ≥38.1°C \[≥100.5°F\] or axillary temperature ≥37.8°C \[≥100.0°F\]) within 72 hours prior to receipt of study vaccine~* has known or suspected impairment of immunological function~* has or his/her mother has human immunodeficiency virus (HIV) infection~* has or his/her mother has hepatitis B surface antigen-positive test~* has known or history of functional or anatomic asplenia~* has a history of autoimmune disease~* has a history or suspected history of neurological disorder~* has received a pneumococcal vaccine prior to study entry~* has received, or is anticipated to need, corticosteroid therapy~* has received a blood transfusion of immunoglobulin products~* has participated in another clinical study of an investigational product

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants received 4 total doses of V114, administered at approximately 2, 4, 6, and 12 to 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).